The American College of Rheumatology (ACR) gout guidelines define gout as a monosodium urate crystal deposition disease diagnosed by joint aspiration showing needle-shaped, negatively birefringent crystals, or by validated imaging. Management follows a treat-to-target model: lower serum urate below 6.0 mg/dL for most patients and below 5.0 mg/dL for those with severe disease. First-line urate-lowering therapy is allopurinol, started at 100 mg daily (50 mg with CKD stage 4 or worse) and titrated every 2 to 5 weeks. Flares are treated with NSAIDs, colchicine, or glucocorticoids, with colchicine dosed 1.2 mg then 0.6 mg one hour later.
What the ACR Guidelines Actually Cover
The ACR published its core gout management guideline in 2020, with a companion quality-of-care and outcome measures paper in 2021 and an updated diagnostic guidance in 2023. These documents replaced the 2012 ACR recommendations and represent the largest evidence synthesis in gout to date, covering 42 recommendations across diagnosis, treatment, and monitoring.
The guideline is explicitly conditional in most places. That matters: a strong recommendation means the benefit clearly outweighs harm; a conditional recommendation means it probably does, but clinical judgment carries more weight. Roughly two-thirds of the recommendations are conditional, so "the ACR says" is often weaker than it sounds.
The scope runs from crystal-proven diagnosis through urate-lowering therapy (ULT), flare prophylaxis, and lifestyle modification. It does not cover asymptomatic hyperuricemia in detail, and that gap is deliberate — see the misconceptions section.
The Mechanism: Why Urate Crystallizes
Uric acid is the end product of purine metabolism in humans, who lost the uricase enzyme roughly 15 million years ago. Serum urate saturates at approximately 6.8 mg/dL at 37°C (98.6°F), but crystals can form well below that in joint tissue, where temperature runs 1 to 3°C cooler and pH is slightly lower during inflammation. This is why the guideline's 6.0 mg/dL target sits comfortably below the physical saturation point — a margin, not a magic number.
Monosodium urate crystals activate the NLRP3 inflammasome, which cleaves pro-IL-1β into active IL-1β. That cytokine cascade drives the neutrophil influx responsible for the classic hot, red, exquisitely tender joint. In plain terms: the crystal is the spark, and the immune system's IL-1 response is the fire. Colchicine and IL-1 inhibitors both work by interrupting this specific pathway, which is why they succeed where the mechanism predicts.
Crystal deposition begins years before the first flare. Asymptomatic deposition has been documented in up to 25% of people with serum urate above 7.0 mg/dL, meaning the disease process predates the symptom by a median of several years.
Diagnostic Thresholds and Evidence
The ACR recommends joint aspiration with polarized light microscopy as the reference standard for diagnosis. The crystals are needle-shaped and negatively birefringent under compensated polarized light — a property that distinguishes urate from calcium pyrophosphate, which is rhomboid and positively birefringent.
| Diagnostic modality | Result supporting gout | Sensitivity | Specificity | Role in ACR guidance |
|---|---|---|---|---|
| Joint aspiration, polarized microscopy | Needle-shaped, negatively birefringent crystals | 84% in experienced hands | Nearly 100% | Reference standard |
| Dual-energy CT | Monosodium urate deposits coded green | 87% | 95% | Useful when aspiration not feasible |
| Ultrasound, double-contour sign | Hyperechoic band over hyaline cartilage | 68-78% | 87-93% | Supportive, operator dependent |
| Serum urate | Above 6.8 mg/dL during flare | Low | Low | Cannot confirm or exclude gout |
| Clinical criteria (2015 ACR/EULAR) | Score of 8 or more points | 92% | 89% | Valid when crystals unavailable |
The non-obvious detail: a normal serum urate during an acute flare does not exclude gout. Serum urate falls by up to 2.0 mg/dL during an attack because of the acute inflammatory response. Roughly 14% of patients with confirmed gout have a serum urate below 6.0 mg/dL at the time of flare. The guideline warns against using a single urate value drawn mid-flare as a rule-out.
The 2015 ACR/EULAR classification criteria exist for research and for clinical use when aspiration fails. They give weight to the classic first metatarsophalangeal joint involvement, a monosodium urate-positive ultrasound or DECT, and a serum urate above 6.0 mg/dL, among other items.
Quantified Context: Who Gout Affects and How Much
Gout prevalence in the United States is approximately 3.9%, or about 9.2 million adults, per the most recent national estimates. It is the most common inflammatory arthritis in men over 40. Incidence has roughly doubled since the 1970s, tracking with rising obesity and metabolic syndrome rates.
The comparison that matters most for resource decisions: flare frequency falls from a mean of 2 to 3 attacks per year in untreated patients to fewer than 1 per year within 12 months of achieving serum urate below 6.0 mg/dL. That is a relative reduction of roughly 60 to 70%, and it is the number that justifies the titration schedule.
Sex differences are real but smaller than commonly assumed. Men have a 3 to 4 times higher prevalence than women before age 65. After menopause, the female incidence rises sharply because estrogen promotes renal urate excretion; by age 80, the sex gap narrows to roughly 1.5 to 1.
| Population | Approximate prevalence | Median age at onset (men) |
|---|---|---|
| US adults overall | 3.9% | 45 to 50 years |
| Men over 40 | 5.2% | 45 to 50 years |
| Postmenopausal women | 3.0% | 60 to 65 years |
| Adults with CKD stage 3 or worse | 11-13% | 55 to 60 years |
| Patients on thiazide diuretics | 4-6% | 50 to 60 years |
| Kidney transplant recipients | 7-10% | Any age |
The Time Course: Flare, Treat, Target, Remission
Gout has a recognizable clinical arc. The timeline below reflects the intervals the ACR cites, not idealized marketing claims.
| Phase | Typical timing | What happens | ACR guidance point |
|---|---|---|---|
| Asymptomatic hyperuricemia | Months to years | Urate rises, no symptoms | No ULT recommended |
| First flare | 12 to 24 hours to peak | MTP-1 joint swollen, red, tender | Treat immediately, do not wait for confirmation |
| Intercritical period | Days to years | Symptoms resolve fully | Prophylaxis if ULT started |
| ULT titration | Every 2 to 5 weeks | Dose up until urate target | Measure urate 2 to 5 weeks after each change |
| Target achieved | Median 3 to 6 months | Urate below 6.0 mg/dL | Continue therapy indefinitely |
| Flare-free stability | 3 to 12 months | No attacks, tophi may shrink | Prophylaxis can be discontinued after 3 to 6 months |
| Tophus resolution | 12 to 24 months at target | Tophi shrink or resolve | Continue treatment; do not stop for tophi alone |
The actionable implication: if you start allopurinol today at 100 mg, plan on measuring urate in 2 to 5 weeks, adjusting, measuring again, and expecting 3 to 6 months to reach target. Patients who expect to "be fixed" in two weeks will be disappointed, and the guideline is explicit that stopping early is a common and avoidable failure mode.
Urate-Lowering Therapy: Agents, Doses, and Trade-offs
The ACR recommends allopurinol as first-line ULT for essentially all patients, including those with chronic kidney disease, with dose adjustment rather than avoidance. This is a meaningful change from older practice, where allopurinol was often withheld in CKD out of fear of hypersensitivity.
| Agent | Starting dose | Titration | Max dose | Key caveat |
|---|---|---|---|---|
| Allopurinol | 100 mg/day (50 mg if CKD 4+) | Every 2 to 5 weeks | 800 mg/day per label; up to 800 mg titratable | HLA-B*58:01 screening recommended in Han Chinese, Thai, and Korean patients |
| Febuxostat | 40 mg/day | Every 2 to 4 weeks | 80 mg/day | Boxed warning for cardiovascular death in patients with existing CVD; use cautiously |
| Probenecid | 250 mg twice daily | Every 1 to 2 weeks | 2 g/day | Requires adequate renal function; not for CKD 3+ |
| Pegloticase | 8 mg IV every 2 weeks | Fixed dosing | 8 mg every 2 weeks | Reserved for refractory tophi; risk of infusion reactions |
The HLA-B58:01 detail is the most clinically important safety item in the guideline. Allopurinol hypersensitivity syndrome (AHS) is rare but carries a mortality rate of roughly 20 to 25%. The HLA-B58:01 allele raises that risk substantially in specific East Asian and Southeast Asian populations. The ACR recommends screening before starting allopurinol in those groups — a step that costs roughly USD 100 to 200 and prevents a syndrome that kills one in four who develop it.
The febuxostat cardiovascular warning deserves context. The CARES trial (White et al., 2018) found higher cardiovascular and all-cause mortality with febuxostat versus allopurinol in patients with existing cardiovascular disease. The FDA added a boxed warning in 2019. Febuxostat remains useful for patients who cannot tolerate allopurinol, but the ACR does not position it as first-line.
Variations and Edge Cases
Kidney disease is the single most consequential variation. The ACR explicitly recommends titrating allopurinol in CKD rather than switching agents, provided the dose is started low and increased gradually. Patients with CKD stage 3 or worse have gout prevalence of 11 to 13%, roughly triple the general population.
Heart failure and diuretic use are a second cluster. Thiazide and loop diuretics raise serum urate by reducing renal excretion, and about 20 to 30% of patients with treatment-resistant gout are on one. The guideline recommends switching to losartan, which has a mild uricosuric effect, or to a calcium channel blocker, when the diuretic can be replaced.
Organ transplant patients represent a third edge case. Calcineurin inhibitors (tacrolimus, cyclosporine) raise urate, and drug interactions with azathioprine limit allopurinol use — the combination can cause severe myelosuppression because allopurinol blocks azathioprine's metabolism. This is where febuxostat or low-dose allopurinol with careful monitoring becomes necessary.
Pregnancy is rarely covered but deserves a sentence: gout is uncommon in pregnancy, and the ACR guidance does not establish a preferred ULT in pregnancy. Colchicine is generally considered compatible; allopurinol should be avoided unless clearly needed.
Misconceptions the Guidelines Correct
First misconception: asymptomatic hyperuricemia should be treated. The ACR recommends against starting ULT in patients with hyperuricemia but no gout, no tophi, and no history of flares. This is a strong recommendation, and it runs contrary to a lot of direct-to-consumer messaging.
Second misconception: a low-purine diet alone can control gout. Dietary change typically lowers serum urate by 10 to 15%, or roughly 0.5 to 1.0 mg/dL in a patient starting at 8.0 mg/dL. That is not usually enough to reach the 6.0 mg/dL target without medication, though diet remains additive and important.
Third misconception: stop allopurinol during a flare. The ACR recommends continuing ULT during a flare if the patient is already on it, and does not recommend stopping. Starting ULT during a flare is also acceptable, provided prophylaxis is given.
Fourth misconception: cherries and vitamin C replace treatment. The evidence for cherry extract shows urate reductions in the range of 0.2 to 0.5 mg/dL in small studies — a magnitude that will not substitute for titration, and the guideline does not endorse it as a stand-alone strategy.
What to Actually Do
Concrete steps that match the guideline and are worth writing down:
- Confirm the diagnosis with joint aspiration when feasible; if not feasible, use the 2015 ACR/EULAR criteria and DECT or ultrasound to support a clinical diagnosis, and treat immediately when suspicion is high.
- Start a flare treatment within 24 to 36 hours of symptom onset for maximum effect: NSAID at full dose, colchicine 1.2 mg then 0.6 mg at one hour, or oral glucocorticoid at 0.5 mg/kg/day for 5 to 10 days.
- Screen for HLA-B*58:01 before allopurinol in patients of Han Chinese, Thai, or Korean descent, and consider screening in other high-risk groups.
- Start allopurinol at 100 mg daily (50 mg if CKD stage 4 or worse) and titrate every 2 to 5 weeks until serum urate is below 6.0 mg/dL for most patients or below 5.0 mg/dL for those with tophi or severe disease.
- Prescribe flare prophylaxis (colchicine 0.5 to 0.6 mg once or twice daily, or an NSAID) for the first 3 to 6 months of ULT and continue until the patient is flare-free at target.
- Measure serum urate 2 to 5 weeks after each dose change and again once stable; do not stop ULT because a flare occurred after starting it, since early flares during titration are common and expected.
Red-flag warning signs that require urgent evaluation rather than routine management:
- A first attack in a joint other than the big toe with fever above 101°F, which may indicate septic arthritis and requires aspiration before treatment.
- Allopurinol rash, fever, eosinophilia, or mucosal involvement, which can signal hypersensitivity syndrome and is a medical emergency.
- Sudden severe back or flank pain in a patient with known tophi, which can indicate urate nephrolithiasis.
- New shortness of breath or leg swelling in a patient on febuxostat with a cardiovascular history.
- Inability to bear weight or rapid joint destruction on imaging, which suggests a tophaceous or infected joint rather than a routine flare.
Limitations of the Evidence
The 2020 ACR guideline is built largely on moderate- and low-certainty evidence. Several recommendations rest on observational data and expert consensus rather than randomized trials. The allopurinol-versus-febuxostat cardiovascular question is settled only for patients with existing cardiovascular disease, not for the general gout population. The optimal duration of prophylaxis after starting ULT is uncertain beyond 3 to 6 months. The role of newer IL-1 inhibitors in acute flares is promising but not yet a first-line recommendation. And the guideline does not resolve whether a lower target than 6.0 mg/dL improves long-term outcomes in patients without tophi.
What the guidelines do resolve is the core sequence: confirm the diagnosis, treat the flare early, start allopurinol low and titrate to a defined target, protect against early flares, and stay on therapy. The numbers that matter most are 6.0 mg/dL, 100 mg, 2 to 5 weeks, and 3 to 6 months — and they are all in the same paragraph for a reason: gout control is a titration problem before it is anything else.